Spectrum Pharma (SPPI) Tops Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spectrum Pharmaceuticals (SPPI) PT, Estimate Cut at Jefferies
March 16, 2015 9:10 AM EDTJefferies analyst Ryan Martins lowered estimates and his price target on Hold-rated Spectrum Pharmaceuticals (NASDAQ: SPPI) to $6.00 (from $8.00) following Q4 results.
Martins commented, "We have lowered our PT to $6 from $8 as we have risk adjusted Fusilev sales after 2Q15 (20% probability of achieving our... More
